帕金森病认知下降风险患者的淡漠评分与β-淀粉样蛋白沉积相关
本横断面研究纳入64例无痴呆但存在至少1项帕金森病痴呆危险因素的帕金森病患者,通过多模态PET成像和临床评估发现,淡漠评分与全局β-淀粉样蛋白负荷独立相关,且与双侧伏隔核、额下回和扣带回皮质的β-淀粉样蛋白结合相关。
要点
- 淡漠评分与β-淀粉样蛋白沉积独立相关,不受抑郁和焦虑影响
- 区域关联最显著位于双侧伏隔核、额下回和扣带回皮质
- 淡漠可能源于β-淀粉样蛋白病理,解释其对多巴胺能和抗抑郁治疗抵抗
核心结论
- 在存在认知下降风险的帕金森病患者中,淡漠与β-淀粉样蛋白沉积独立相关。
研究设计与样本
- 横断面研究纳入64例帕金森病患者,其中48例男性、16例女性,平均年龄69.2±6.7岁,Hoehn & Yahr分期2.7±0.5,蒙特利尔认知评估评分25.3±3.0。
- 患者基于至少1项帕金森病痴呆危险因素招募,但排除痴呆患者。
- 所有患者接受[11C]匹兹堡化合物B β-淀粉样蛋白、[11C]二氢丁苯那嗪VMAT2和[11C]甲基4哌啶基丙酸酯乙酰胆碱酯酶脑PET成像及临床评估。
主要发现
- 平均淡漠评分25.4±6.4,主要反映亚临床淡漠。
- 淡漠评分与淀粉样蛋白结合、认知、抑郁和焦虑评分相关,但与年龄、病程、纹状体VMAT2或胆碱能结合无显著相关。
- 多元回归模型(p<0.0001)显示全局β-淀粉样蛋白负荷(p=0.0038)、全局认知z评分(p=0.028)和焦虑(p=0.038)有显著效应,抑郁评分无显著效应。
- 基于体素的分析显示淡漠评分与双侧伏隔核、额下回和扣带回皮质的β-淀粉样蛋白结合稳健相关(FWE校正p<0.005)。
临床怎么用
- 对帕金森病患者评估淡漠时,应考虑β-淀粉样蛋白病理作为潜在原因,尤其当对多巴胺能和抗抑郁治疗反应不佳时。
- 淡漠评分结合β-淀粉样蛋白PET成像可能有助于识别认知下降风险较高的帕金森病患者。
局限性
- 横断面设计无法确定因果关系。
- 样本量较小(n=64),且患者基于痴呆风险因素招募,结果可能不适用于所有帕金森病患者。
- 淡漠评分主要反映亚临床淡漠,结论推广至临床显著淡漠需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether β-amyloidopathy correlates with apathy rating scores independently of mood changes and other neurodegenerative processes in Parkinson disease (PD). METHODS: In this cross-sectional study, patients with PD (n = 64, 48 male and 16 female, mean age 69.2 ± 6.7 years, Hoehn & Yahr stage 2.7 ± 0.5, Montreal Cognitive Assessment score 25.3 ± 3.0) underwent [11C]Pittsburgh compound B β-amyloid, [11C]dihydrotetrabenazine vesicular monoamine transporter type 2 (VMAT2), and [11C]methyl 4 piperidinyl propionate acetylcholinesterase brain PET imaging and clinical assessments, including the Marin Apathy Evaluation Scale, Clinician Version. Patients were recruited on the basis of having at least 1 risk factor for PD dementia, but they were excluded if they had dementia. RESULTS: Mean apathy rating score was 25.4 ± 6.4, reflecting predominantly subclinical apathy. Apathy rating scale scores correlated with amyloid binding, cognitive, depressive, and anxiety scores but not significantly with age, duration of disease, striatal VMAT2, or cholinergic binding. Multiple regression analysis model (p < 0.0001) showed significant regressor effects for global β-amyloid burden (p = 0.0038) with significant covariate effects for global cognitive z scores (p = 0.028) and for anxiety (p = 0.038) but not with depressive scores. Voxel-based analysis showed robust correlation between apathy rating scale scores and β-amyloid binding in bilateral nuclei accumbens, inferior frontal, and cingulate cortices (family-wise error rate-corrected p < 0.005). CONCLUSION: Apathy is independently associated with β-amyloidopathy in patients with PD at risk of dementia. Regional brain findings are most robust for β-amyloidopathy in the nuclei accumbens, inferior frontal, and cingulate regions. Findings may provide an explanation for the often treatment-refractory nature of apathy in advancing PD despite optimized dopaminergic and antidepressant pharmacotherapy. CLINICALTRIALSGOV IDENTIFIER: NCT01565473.
引用
- Zhou Z, Müller MLTM, Kanel P, et al. Apathy rating scores and β-amyloidopathy in patients with Parkinson disease at risk for cognitive decline. Neurology. 2019. PMID: 31732566. doi:10.1212/WNL.0000000000008683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。